Rapamycin's Cardiovascular Benefits: What the 2025–2026 Human Trials Actually Show

Rapamycin has been the most validated longevity compound in animal research for over a decade. The NIA Interventions Testing Program confirmed a consistent 15–20% lifespan extension in mice across three independent sites. But the question longevity researchers have been asking for years is: what does it actually do in humans?

In 2025, we finally got meaningful data — and the results are more nuanced than either the optimists or the critics predicted.

The GeroScience Pilot: Cardiovascular Benefits at 1mg/Day

A small but carefully designed proof-of-concept trial published in GeroScience (2025) tested whether short-term mTOR inhibition with very low-dose rapamycin could improve cardiovascular and endothelial function in healthy older men aged 70–76.

Six participants took 1 mg of rapamycin daily for 8 weeks. That's a tiny fraction of the immunosuppressive doses used in transplant medicine (typically 2–5 mg/day). The results surprised even the researchers:

The speed of the cardiovascular response is notable. If the effects were purely metabolic (fat loss, insulin sensitivity), you'd expect changes to lag months. The rapid cardiovascular improvement suggests a more direct mechanism — possibly direct mTOR pathway effects on cardiomyocyte function and vascular senescence clearance.

The PEARL Trial: 48 Weeks of Intermittent Rapamycin in Healthy Adults

The PEARL Trial (48-week, double-blind, randomized, placebo-controlled) is the most rigorous human longevity trial for rapamycin to date. Published in 2025, it tested once-weekly oral rapamycin at 5 mg or 10 mg in healthy adults aged approximately 50–85 years.

The primary endpoint (visceral fat) missed. But the secondary outcomes — particularly lean mass preservation and subjective health improvements in women — are clinically meaningful signals for a compound targeting the aging process itself.

Why Bryan Johnson's Withdrawal Matters (And Doesn't)

In early March 2026, Bryan Johnson publicly announced he was dropping rapamycin from his protocol after experiencing hair loss, impaired wound healing, and metabolic side effects. This generated significant media attention in the longevity community.

A few important context points:

That said, the side effects Johnson reported — hair loss, wound healing delays — are consistent with known immunosuppressive effects at higher doses. This is a legitimate warning about dose escalation without medical supervision.

The NIA ITP: 20 Years of Gold-Standard Data

A March 2026 Journal of Gerontology synthesis of 20 years of Interventions Testing Program research (54 compounds tested across 3 independent sites) confirmed the hierarchy:

• Rapamycin: Most reliable lifespan extender across both sexes — ~15–20% increase
• Rapamycin + Acarbose: Best combination — up to 36.6% median lifespan increase
• SGLT2 inhibitors: 13.6% increase in male mice (human trial data emerging)
• Recent ITP failures (2026): Astaxanthin, AKG, pioglitazone, mifepristone — all failed to extend mouse lifespan

The combination finding is particularly important: rapamycin + acarbose doesn't just add — it multiplies. This supports the multi-pathway approach to aging intervention.

What This Means for Your Protocol in 2026

Based on the current human trial data, here's a practical evidence-based framework:

The VITAL-H Trial: Answers Coming 2028–2030

The most important upcoming data point in longevity medicine is the VITAL-H Trial — a $38M Phase 3 study funded by ARPA-H comparing:

• Rapamycin (mTOR inhibitor)
• Semaglutide (GLP-1 agonist)
• Dapagliflozin (SGLT2 inhibitor)
• Placebo

726 adults aged 60–65. Primary outcome: biological aging (methylation clock, functional decline). Results expected 2028–2030. This will be the definitive comparison of the leading longevity drug candidates in humans.

Bottom Line

The 2025–2026 human data on rapamycin is genuinely promising — particularly the cardiovascular findings, which appeared faster than expected and at very low doses. The PEARL Trial's safety data provides reasonable confidence that weekly low-dose rapamycin is not harmful in healthy adults.

However, three things remain true:

1. The optimal dose/frequency is unknown — we don't have definitive human longevity trial results yet (VITAL-H runs through 2030)
2. Bryan Johnson's experience shows dose escalation is risky — more is not better
3. Physician supervision is non-optional — rapamycin affects immune function and has real drug interactions

For most healthy adults under 60 without cardiovascular risk factors, the evidence currently favors starting with better-characterized Tier 1 interventions: Zone 2 cardio 150+ min/week, GlyNAC (glycine + NAC), creatine, NMN+TMG, and magnesium glycinate — before considering rapamycin.